EMD Stock Overview
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Emyria Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.033 |
| 52 Week High | AU$0.074 |
| 52 Week Low | AU$0.027 |
| Beta | 0.81 |
| 1 Month Change | -15.38% |
| 3 Month Change | 10.00% |
| 1 Year Change | -50.75% |
| 3 Year Change | -92.24% |
| 5 Year Change | n/a |
| Change since IPO | -77.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| EMD | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -10.8% | -1.6% | 0.3% |
| 1Y | -50.7% | -10.3% | 9.1% |
Return vs Industry: EMD underperformed the Australian Pharmaceuticals industry which returned -8.4% over the past year.
Return vs Market: EMD underperformed the Australian Market which returned 9.5% over the past year.
Price Volatility
| EMD volatility | |
|---|---|
| EMD Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.9% |
| 10% least volatile stocks in AU Market | 3.0% |
Stable Share Price: EMD's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: EMD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Michael Winlo | emyria.com |
Emyria Limited engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia. It develops MDMA-inspired medicines, including EMD-MX1, for faster-acting MDMA with improved side-effect profile for drug-assisted therapies; EMD-MX2, an adjunct for Parkinson’s disease to improve side effects of a common treatment; and EMD-MX3 for other neurological indications. The company is also developing EMD-RX7/9, a CBD capsule prescription medicines for complex pain and anxiety which is under preclinical trial program; and provides psychological trauma care facility under the Pax Centre name.
Emyria Limited Fundamentals Summary
| EMD fundamental statistics | |
|---|---|
| Market cap | AU$15.20m |
| Earnings (TTM) | -AU$11.46m |
| Revenue (TTM) | AU$2.20m |
6.9x
P/S Ratio-1.3x
P/E RatioIs EMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EMD income statement (TTM) | |
|---|---|
| Revenue | AU$2.20m |
| Cost of Revenue | AU$2.37m |
| Gross Profit | -AU$167.55k |
| Other Expenses | AU$11.29m |
| Earnings | -AU$11.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.025 |
| Gross Margin | -7.61% |
| Net Profit Margin | -520.07% |
| Debt/Equity Ratio | 33.5% |
How did EMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 07:16 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Emyria Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|